Despite advances in therapy, outcomes in dilated cardiomyopathy (DCM) remain poor [@bib1]. DCM is a heterogeneous disease affecting a diverse group of patients and response to therapy is varied [@bib2]. Precise phenotyping, enabling targeted and personalized management to improve outcomes and avoid unnecessary interventions remains a therapeutic goal [@bib3].

Late gadolinium enhancement (LGE)-cardiovascular magnetic resonance (CMR) detects nonischemic LGE in approximately 30% of patients, which correlates with replacement fibrosis on histology [@bib1], [@bib4]. LGE provides incremental value in addition to left ventricular ejection fraction (LVEF) for predicting all-cause mortality and sudden cardiac death (SCD) events; therefore, it has the potential to guide therapy such as during the selection of patients for implantable cardioverter-defibrillators (ICDs) [@bib1], [@bib4].

Nonischemic LGE most often occurs in a linear pattern in the mid-wall of the septum; however, sub-epicardial patterns and LGE occurring in the free-wall of the left ventricle (LV) are also recognized. The nature of the dose-response relationship between LGE and outcome is poorly understood. Data examining the association between the location and pattern of LGE and specific clinical outcomes are also lacking. Identifying an amount, location, or pattern of LGE that provides the optimal mode of risk stratification will help guide the use of this technique in clinical practice.

Methods {#sec1}
=======

Consecutive patients with DCM referred to our unit between 2000 and 2011 were screened for a registry. All participants provided written informed consent and the study was approved by the National Research Ethics Service. The diagnosis of DCM was confirmed using the World Health Organization/International Society and Federation of Cardiology definition, based on reduced LVEF and elevated LV end-diastolic volume indexed to body surface area (BSA) (LVEDVi), compared to published age- and sex-specific reference values [@bib5]. Exclusion criteria ([Figure 1](#fig1){ref-type="fig"}) included ischemic heart disease, defined as a stenosis of \>50% in a major coronary artery or evidence of inducible ischemia on functional testing; evidence of acute myocarditis, or ongoing inflammatory myocardial disease; hypertrophic cardiomyopathy; arrhythmogenic right ventricular cardiomyopathy; significant valve disease; and infiltrative disease. In keeping with guidelines [@bib6], [@bib7], an ischemic etiology was considered in all patients and ruled out as follows: All those with infarct patterns of LGE were excluded. Additionally, 681 (77.9%) underwent coronary angiography and 63 (7.2%) perfusion imaging or stress echocardiography without provocation of ischemia. All of the remaining patients (n = 130) were free of angina and considered to have a low risk of ischemic heart disease by their attending cardiologists; the majority (n = 82) were 40 years of age or younger. In the absence of a class 1 indication, coronary angiography was not performed [@bib6], [@bib7]. None of these patients underwent coronary revascularization or suffered an acute coronary syndrome during follow-up. The final cohort included 682 from previous studies, all of whom underwent extended follow-up for this study [@bib1], [@bib4].Figure 1Study CohortFlow chart detailing the identification of the study cohort.

CMR was performed on a 1.5-T system (Sonata/Avanto, Siemens, Erlangen, Germany) using a standardized protocol [@bib4]. Late gadolinium imaging was performed 10 min after intravenous injection of 0.1 mmol/kg of gadopentetate dimeglumine or gadobutrol (Bayer AG, Berlin, Germany) using an inversion-recovery gradient echo sequence. Images were acquired in standard long-axis planes and consecutive short axis slices (8-mm slice thickness with 2-mm gap) in 2-phase encoding directions. Inversion times were optimized to null the myocardium. Ventricular volumes and mass and left atrial volumes were calculated using dedicated software (CMRtools, Cardiovascular Imaging Solutions, London, United Kingdom) and indexed to BSA. The presence of nonischemic LGE was determined by 2 independent operators, with a third providing adjudication if necessary. LGE was considered present if seen in both long- and short-axis planes, in 2 phase-encoding directions, and extending beyond the localized ventricular insertion areas. A senior operator categorized the location and pattern of LGE. The location was classified as septal, LV free-wall, or as occurring in both locations. The pattern was classified as linear mid-wall, sub-epicardial, focal, or as occurring in multiple patterns. LGE quantification was performed by 2 senior operators using the full width at half maximum method (CMR42, Circle Cardiovascular Imaging Inc., Calgary, Canada).

Patients were followed-up from baseline using questionnaires and telephone interviews, and by gathering information from family physicians, cardiologists, and hospital records. Deaths were confirmed using the UK Health and Social Care Information Service. Follow-up time was calculated from the baseline scan until an endpoint occurred or last contact with the patient. All outcome events were adjudicated by a committee of cardiologists blinded to CMR data. The primary outcome of interest was all-cause mortality. The cause of death was confirmed from a combination of medical records, death certification, and postmortem results using American College of Cardiology/American Heart Association guidance [@bib8]. The secondary endpoint was an SCD composite including SCD and aborted SCD. SCD was defined as "unexpected death either within 1 h of the onset of cardiac symptoms in the absence of progressive cardiac deterioration; during sleep; or within 24 h of last being seen alive" [@bib9]. Aborted SCD was defined as "an appropriate ICD shock for ventricular arrhythmia, successful resuscitation following ventricular fibrillation or spontaneous sustained ventricular tachycardia causing hemodynamic compromise and requiring cardioversion" [@bib8].

Statistical analysis {#sec1.1}
--------------------

To examine the association between LGE extent and outcome, patients with LGE were classified based on the percentage of total myocardial mass occupied by LGE to produce equal tertiles of LGE (\>0 and \<2.55%, ≥2.55% and \<5.10%, and ≥5.10%). Baseline characteristics were compared using the Kruskal-Wallis rank test for continuous data and the Fisher exact test for categorical data. The associations between the extent, location, and pattern of LGE were examined using proportional hazard modelling. Models were adjusted for LVEF, age, and sex given the potential to confound the association between LGE and outcome. As part of a sensitivity analysis, the models were also adjusted for LVEF, age, sex, right ventricular ejection fraction (RVEF), New York Heart Association (NYHA) functional class, LVEDVi, LV mass index, and indexed left atrial volume (LAVi). Results are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). A p value of \<0.05 was considered significant. A cubic spline model was fitted to the observed data examining the association between LGE extent and outcome. The cutoff percentage extent of LGE giving the largest C-statistic for the prediction of each end-point was calculated from 1,000 bootstrap samples. The concordance statistic (C-statistic) measured the degree to which a model can distinguish between cases and controls, taking values between 0.5 and 1.0, with larger values indicating better discrimination. The Akaike information criterion (AIC) was used to compare models [@bib10]. The AIC allows comparison of nested and non-nested models and reduces the potential of over-fitting the data. Smaller values indicate the optimal model. Interobserver variability in LGE quantification was examined in a random sample of 60 patients with LGE who had quantification performed by both operators, including 20 from each of the group based on extent. The intraclass correlation coefficient was calculated for continuous variables and the Kappa coefficient for categorical variables.

Results {#sec2}
=======

The final cohort comprised 874 patients, of whom 588 (67.3%) were men, the median LVEF was 39% (interquartile range: 29% to 50%), and nonischemic LGE was present in 300 (34.3%). Baseline characteristics are presented in [Table 1](#tbl1){ref-type="table"}. Patients with LGE were older (p = 0.023), more likely to be men (p \< 0.0001), and prescribed loop diuretics (p \< 0.0001) or mineralocorticoid receptor antagonists (p = 0.008), had lower systolic pressures (p = 0.010) and diastolic blood pressures (p = 0.026), worse NYHA functional class (p = 0.010), lower LVEF (p \< 0.0001), and greater LVEDVi (p \< 0.0001).Table 1Baseline CharacteristicsLGEp Value[∗](#tbl1fnlowast){ref-type="table-fn"}No LGE (n = 574)0.00-2.55% (n = 100)2.55-5.10% (n = 100)\>5.10% (n = 100)Age, yrs51.0 ± 15.152.8 ± 14.453.7 ± 14.656.2 ± 14.60.023Male352 (61.3)80 (80.0)75 (75.0)81 (81.0)\<0.0001BSA, m^2^1.95 ± 0.242.03 ± 0.261.97 ± 0.201.93 ± 0.210.009Heart rate, beats/min73.3 ± 13.974.9 ± 15.673.1 ± 16.070.8 ± 14.10.26Systolic blood pressure, mm Hg121.5 ± 17.6120.0 ± 16.6117.8 ± 17.5115.8 ± 17.30.010Diastolic blood pressure, mm Hg73.2 ± 11.072.2 ± 9.771.1 ± 10.570.0 ± 11.10.026Atrial fibrillation/flutter108 (18.8)23 (23.0)21 (21.0)17 (17.0)0.67Hypertension117 (20.4)25 (25.0)27 (27.0)21 (21.0)0.39Diabetes43 (7.5)17 (17.0)10 (10.0)9 (9.0)0.033Family history of DCM52 (9.1)15 (15.0)11 (11.1)8 (8.0)0.27Family history of SCD43 (7.5)5 (5.0)7 (7.1)8 (8.0)0.85LBBB170 (29.7)29 (29.0)33 (33.0)24 (24.2)0.59Moderate alcohol excess64 (11.1)10 (10.0)14 (14.0)12 (12.0)0.80Previous chemotherapy25 (4.4)6 (6.0)1 (1.0)2 (2.0)0.41Peripartum diagnosis14 (2.4)2 (1.0)0 (0)1 (1.0)0.54Neuromuscular disease6 (1.0)0 (0)1 (1.0)1 (1.0)0.94Medications Beta-blocker407 (71.0)76 (76.0)75 (75.0)79 (79.0)0.32 ACE inhibitor409 (71.3)73 (73.0)72 (72.0)71 (71.0)0.99 ARB117 (20.5)18 (18.0)21 (21.0)24 (24.0)0.76 Loop diuretic209 (36.4)63 (63.0)56 (56.0)59 (59.0)\<0.0001 Aldosterone antagonist173 (30.2)41 (41.0)43 (43.0)41 (41.0)0.008NYHA functional class I254 (44.4)33 (33.7)33 (33.0)34 (34.3)0.010 II229 (40.0)46 (46.9)38 (38.0)41 (41.4) III/IV89 (15.6)19 (19.4)29 (29.0)24 (24.2)CMR measurements LVEF, %40.6 ± 12.134.4 ± 13.335.3 ± 13.135.3 ± 12.1\<0.0001 LVEDVi, ml/m^2^126.3 ± 36.6147.9 ± 46.1142.8 ± 49.8135.5 ± 37.3\<0.0001 LV mass index, g/m^2^93.0 ± 27.7108.6 ± 27.0100.3 ± 24.095.7 ± 25.5\<0.0001 RVEF, %52.4 ± 13.648.5 ± 16.547.7 ± 15.450.6 ± 13.90.033 RVEDVi, ml/m^2^87.9 ± 24.594.6 ± 25.893.8 ± 30.186.4 ± 27.90.007 LAVi, ml/m^2^63.6 ± 25.074.3 ± 29.769.3 ± 25.868.5 ± 27.0\<0.0001[^1][^2][^3]

LGE was present only in the septum in 142 (16.2%) cases, only in the LV free-wall in 42 (4.8%), and in both locations in 116 (13.3%) ([Figure 2](#fig2){ref-type="fig"}). LGE was categorized as linear mid-wall in 185 (21.1%) cases, sub-epicardial in 25 (2.9%), focal in 22 (2.5%), and as occurring in multiple patterns in a further 68 (7.8%) ([Figure 2](#fig2){ref-type="fig"}).Figure 2Late Gadolinium Enhancement in Dilated CardiomyopathyLate gadolinium enhancement images showing **(A)** linear mid-wall enhancement in the septum, **(B)** sub-epicardial enhancement in the lateral wall, **(C)** focal enhancement of the inferior wall, and **(D)** mid-wall enhancement of the septum, lateral and inferior wall.

There was agreement between 2 operators on the presence of LGE in 94.7% of cases (n = 828). There was an absolute mean difference of 0.87% between operators in the quantification of the extent of LGE (intraclass correlation coefficient: 0.87) ([Supplemental Figure 1, Supplemental Table 1](#appsec1){ref-type="sec"}). Additionally, there was 86.7% agreement in categorizing the LGE extent within 3 groups (\>0 and \<2.55%, ≥2.55% and \<5.10%, and ≥5.10%) (Kappa coefficient: 0.80) ([Supplemental Table 2](#appsec1){ref-type="sec"}).

All-cause mortality {#sec2.1}
-------------------

Over a median follow-up of 4.9 years (interquartile range: 3.5 to 7.0 years), 150 patients (17.2%) died including 77 (25.7%) with LGE and 73 (12.7%) without (HR: 2.39; 95% CI: 1.73 to 3.29; p \< 0.001) ([Supplemental Figure 2A](#appsec1){ref-type="sec"}). Following adjustment for LVEF, age, and sex, LGE was associated with greater all-cause mortality (HR: 1.81; 95% CI: 1.30 to 2.52; p \< 0.001) ([Supplemental Table 3](#appsec1){ref-type="sec"}). The estimated HRs were similar after additionally adjusting for RVEF, NYHA class, LVEDVi, LV mass index, and LAVi as part of a sensitivity analysis ([Supplemental Tables 3 and 4, Supplemental Figure 3](#appsec1){ref-type="sec"}).

### Extent of LGE {#sec2.1.1}

Estimated adjusted HRs for patients with LGE extents of 0 to 2.55%, 2.55% to 5.10%, and \>5.10% were 1.59 (95% CI: 0.99 to 2.55; p = 0.056), 1.56 (95% CI: 0.96 to 2.54; p = 0.072), and 2.31 (95% CI: 1.50 to 3.55; p \< 0.001), respectively, compared to those without LGE ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}, [Supplemental Figure 2B](#appsec1){ref-type="sec"}). Modeling LGE as a linear measure, per percentage increase in extent, underestimated risk in most patients while overestimating risk in the small proportion of patients with the largest extent ([Supplemental Figure 4](#appsec1){ref-type="sec"}). The percentage extent of LGE giving the largest C-statistic for the primary endpoint was 1.29% (C-statistic: 0.70).Figure 3Outcome and Extent of Late Gadolinium EnhancementEstimated adjusted hazard ratios with 95% confidence intervals **(green lines)** for **(A)** all-cause mortality and **(B)** the sudden cardiac death endpoint, per group based on late gadolinium enhancement extent (LGE). Patients are divided into 3 groups based on cut-offs of LGE extent: \>0 and \<2.55%, ≥2.55 and \<5.10%, and ≥5.10%. The hazard ratios for the endpoint are positioned at the median LGE extent within each group. A cubic spline model **(orange line)** has been fitted to the observed data. LVEF = left ventricular ejection fraction; SCD = sudden cardiac death; ASCD = aborted SCD.Figure 4Outcome Related to Extent, Location, and Pattern of Late Gadolinium EnhancementForrest plots showing the estimated adjusted hazard ratios (HRs) for **(A)** all-cause mortality and **(B)** the sudden cardiac death (SCD) endpoint, per patient group based on late gadolinium enhancement (LGE) extent, location, and pattern. For each model the different LGE HRs are compared to the No-LGE group, except for the final model where "septal LGE" is compared to "no-Septal LGE." Abbreviations as in [Figure 3](#fig3){ref-type="fig"}.

### Location of LGE {#sec2.1.2}

Patients with LGE only in the septum, only in the free-wall, and in both locations had adjusted HRs for the primary endpoint of 1.96 (95% CI: 1.32 to 2.92; p \< 0.001), 0.77 (95% CI: 0.28 to 2.12; p = 0.77), and 1.99 (95% CI: 1.30 to 3.04; p = 0.002), compared to those without LGE ([Figure 4](#fig4){ref-type="fig"}, [Supplemental Figure 2C](#appsec1){ref-type="sec"}). A simplified model showed that those patients with septal LGE had an estimated adjusted HR of 2.00 (95% CI: 1.43 to 2.81; p \< 0.0001) compared to those without septal LGE ([Figure 4](#fig4){ref-type="fig"}).

### Pattern of LGE {#sec2.1.3}

Estimated adjusted HRs for patients with linear mid-wall, sub-epicardial, focal, and multiple patterns of enhancement were 1.70 (95% CI: 1.17 to 2.49; p = 0.006), 1.29 (95% CI: 0.47 to 3.57; p = 0.62), 2.85 (95% CI: 1.30 to 6.23; p = 0.009), and 2.00 (95% CI: 1.20 to 3.34; p = 0.008), respectively, compared to those patients without LGE ([Figure 4](#fig4){ref-type="fig"}, [Supplemental Figure 2D](#appsec1){ref-type="sec"}).

The model with the smallest AIC and the most effective for the prediction of the primary endpoint was based on the presence of septal LGE ([Table 2](#tbl2){ref-type="table"}). This was superior to those based on extent or pattern of LGE and the LGE cutoff with the largest C-statistic for the prediction of the primary endpoint. Adding the presence of any LGE and the presence of septal LGE to the baseline multivariable models without LGE improved the C-statistic for the prediction of all-cause mortality ([Supplemental Table 3](#appsec1){ref-type="sec"}).Table 2Individual Proportional Hazard Models Investigating the Association Between All-Cause Mortality and Late Gadolinium EnhancementAdjusted for LVEF, Sex, and AgenMortalityHR (95% CI)Individual p ValueOverall p ValueC-StatisticAICPresence and extent LGE (binary) \[any\]0%57473 (12.7)1.00---\<0.0010.711,790.1\>0%30077 (25.7)1.81 (1.30 -- 2.52)\<0.001 LGE (binary) \[cutoff\]\<1.29%61781 (13.1)1.00---\<0.00010.721,787.6≥1.29%25769 (26.8)1.93 (1.38 -- 2.69)\<0.001 LGE (tertiles)0%57473 (12.7)1.00---0.0010.721,791.5\>0% and \<2.55%10024 (24.0)1.59 (0.99 -- 2.55)0.056≥2.55% and \<5.10%10022 (22.0)1.56 (0.96 -- 2.54)0.072≥5.10%10031 (31.0)2.31 (1.50 -- 3.55)\<0.001Location and pattern LGE (by location)Absent57473 (12.7)1.00---\<0.0010.721,789.7Free-wall only424 (9.5)0.77 (0.28 -- 2.12)0.61Septal only14241 (28.9)1.96 (1.32 -- 2.92)\<0.001Both11632 (27.6)1.99 (1.30 -- 3.04)0.002 LGE (septal)[∗](#tbl2fnlowast){ref-type="table-fn"}No61677 (12.5)1.00---\<0.00010.721,786.0Yes25873 (28.3)2.00 (1.43 -- 2.81)\<0.001 LGE (by pattern)Absent57473 (12.7)1.00---0.0050.711,794.0Sub-epicardial254 (16.0)1.29 (0.47 -- 3.57)0.62Mid-wall18547 (25.4)1.70 (1.17 -- 2.49)0.006Multiple6819 (27.9)2.00 (1.20 -- 3.34)0.008Focal227 (31.8)2.85 (1.30 -- 6.23)0.009[^4][^5][^6][^7]

SCD and aborted SCD {#sec2.2}
-------------------

Overall, 84 patients (9.6%) suffered SCD or aborted SCD, including 55 patients (18.3%) with LGE and 29 (5.1%) without (HR: 4.12; 95% CI: 2.64 to 6.45; p \< 0.001) ([Supplemental Figure 5A](#appsec1){ref-type="sec"}). Following adjustment for LVEF, age, and sex, LGE was associated with SCD and aborted SCD (HR: 3.96; 95% CI: 2.41 to 6.52; p \< 0.001) ([Supplemental Table 5](#appsec1){ref-type="sec"}). The estimated HRs were similar following adjustment for additional covariates as part of a sensitivity analysis ([Supplemental Tables 5 and 6, Supplemental Figure 6](#appsec1){ref-type="sec"}).

### Extent of LGE {#sec2.2.1}

Estimated adjusted HRs for patients with LGE extents of 0 to 2.55%, 2.55% to 5.10%, and \>5.10%, respectively, were 2.79 (95% CI: 1.42 to 5.49; p = 0.003), 3.86 (95% CI: 2.09 to 7.13; p \< 0.0001), and 4.87 (95% CI: 2.78 to 8.53; p \< 0.0001), compared to patients without LGE ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}, [Supplemental Figure 5B](#appsec1){ref-type="sec"}). Modeling LGE as a linear measure, per percentage increase in extent, underestimated risk in most patients while vastly overestimating risk in the proportion of patients with the largest extent ([Supplemental Figure 7](#appsec1){ref-type="sec"}). The percentage extent of LGE giving the largest C-statistic for the prediction of the arrhythmic endpoint was 0.71% (C-statistic: 0.70).

### Location of LGE {#sec2.2.2}

Patients with LGE in the septum (HR: 3.13; 95% CI: 1.68 to 5.81; p \< 0.001) and in both the septum and free-wall (HR: 5.82; 95% CI: 3.30 to 10.27; p \< 0.0001) had greater incidence of the SCD endpoint compared to patients without LGE. Although there was a weaker trend towards increased events in patients with LGE only occurring in the free-wall, this did not reach statistical significance (HR: 2.19; 95% CI: 0.76 to 6.31; p = 0.15) ([Figure 4](#fig4){ref-type="fig"}, [Supplemental Figure 5C](#appsec1){ref-type="sec"}).

### Pattern of LGE {#sec2.2.3}

Estimated adjusted HRs for patients with linear mid-wall, sub-epicardial, focal, and multiple patterns of enhancement were 3.21 (95% CI: 1.82 to 5.66; p \< 0.0001), 5.54 (95% CI: 2.18 to 14.08; p \< 0.001), 3.16 (95% CI: 0.91 to 10.97; p = 0.070), and 5.72 (95% CI: 3.06 to 10.69; p \< 0.0001), respectively, compared to those patients without LGE ([Figure 4](#fig4){ref-type="fig"}, [Supplemental Figure 5D](#appsec1){ref-type="sec"}).

Overall, the model with the smallest AIC that best predicted the SCD endpoint was based on the presence and location of LGE within the septum, the free-wall, or in both locations ([Table 3](#tbl3){ref-type="table"}). This was superior to models based on extent and pattern of LGE. Adding the presence of any LGE and the presence of LGE by location to the baseline multivariable models without LGE improved the C-statistic for the prediction of the SCD composite ([Supplemental Table 5](#appsec1){ref-type="sec"}).Table 3Individual Proportional Hazard Models Investigating the Association Between Sudden Cardiac Death Events and Late Gadolinium EnhancementAdjusted for LVEF, Sex, and AgenSCD/ASCDHR (95% CI)Individual p ValueOverall p ValueC-StatisticAICPresence and extent LGE (binary) \[any\]0%57429 (5.1)1.00---\<0.00010.701027.6\>0%30055 (18.3)3.96 (2.41 -- 6.52)\<0.0001 LGE (binary) \[cutoff\]\<1.29%61730 (5.2)1.00---\<0.00010.701027.6≥1.29%25754 (18.6)3.94 (2.42 -- 6.41)\<0.0001 LGE (tertiles)0%57429 (5.1)1.00---\<0.00010.711028.5\>0% and \<2.55%10013 (13.4)2.80 (1.40 -- 5.62)0.004≥2.55% and \<5.10%10018 (18.2)4.03 (2.16 -- 7.53)\<0.0001≥5.10%10024 (23.1)5.07 (2.86 -- 8.98)\<0.0001Location and pattern LGE (by location)[∗](#tbl3fnlowast){ref-type="table-fn"}Absent57429 (5.1)1.00---\<0.00010.721024.8Free-wall only424 (9.5)2.19 (0.76 -- 6.31)0.15Septal only14221 (14.8)3.13 (1.68 -- 5.81)\<0.001Both11630 (25.9)5.82 (3.30 -- 10.27)\<0.0001 LGE (septal)No61633 (5.4)1.00---\<0.00010.701027.4Yes25851 (19.8)4.06 (2.46 -- 6.71)\<0.0001 LGE (by pattern)Absent57429 (5.1)1.00---\<0.00010.711029.5Focal253 (13.6)3.16 (0.91 -- 10.97)0.070Mid-wall18529 (15.7)3.21 (1.82 -- 5.66)\<0.0001Sub-epicardial685 (20.0)5.54 (2.18 -- 14.08)\<0.001Multiple2218 (26.5)5.72 (3.06 -- 10.69)\<0.0001[^8][^9][^10][^11]

Discussion {#sec3}
==========

This is the largest study to date to examine the association between the extent, location, and pattern of LGE and outcome in a large, well-phenotyped DCM cohort. We show the superiority of models based on the presence and location of LGE for the prediction of all-cause mortality and SCD events over those based on LGE extent and pattern ([Figure 5](#fig5){ref-type="fig"}). Our data also establish a nonlinear association between LGE extent and outcome, with a large increase in risk with small degrees of LGE and less marked increases with greater extents thereafter ([Figure 5](#fig5){ref-type="fig"}). The increase in risk with small amounts of LGE was most marked for SCD events ([Figure 3](#fig3){ref-type="fig"}).Figure 5Late Gadolinium Enhancement and Outcome in DCMOur study of dilated cardiomyopathy patients shows a nonlinear relationship between late gadolinium enhancement (LGE) extent and all-cause mortality and sudden cardiac death (SCD) events with a large increase in risk with small degrees of LGE. We show the superiority of models based on the location of LGE for the prediction of these end-points. DCM = dilated cardiomyopathy; other abbreviations as in [Figure 3](#fig3){ref-type="fig"}.

Previous studies have shown that nonischemic LGE is associated with an increased risk of death and arrhythmic events [@bib1], [@bib11]. It has been proposed that LGE-CMR may be able to improve the selection of patients who benefit from ICD implantation [@bib12]. However, up until now there has been a paucity of data examining the relationship between LGE extent, location, pattern, and specific outcomes.

Our data suggest that measures based on LGE location are better than those based on extent for risk prediction. We show that patients with septal LGE were at highest risk of death whereas those with free-wall LGE were at similar risk to those without LGE. Accordingly, a model based on the presence of septal LGE best predicted all-cause mortality. Whereas septal LGE was also associated with increased SCD events, the greatest risk was seen with concomitant septal and free-wall LGE. A model accounting for the greater risk associated with concomitant LGE in the septum and free-wall was most effective for SCD. Additionally, sub-epicardial or multiple patterns of LGE were associated with a high-risk of SCD events. These data add important new information on how to best to use LGE-CMR in risk stratification, an area of unmet need [@bib12], [@bib13].

Similar to our results, septal LGE has been associated with worse prognosis in myocarditis [@bib14]. The variation in risk based on location may be explained by differences in etiological substrate, scar microstructure, and geographical effects. Idiopathic DCM is most commonly associated with septal mid-wall LGE whereas a previous episode of myocarditis, the cause of a third of DCM, is often associated with free-wall LGE [@bib15]. Different insults may create fibrosis with different microstructures and varying levels of risk. Septal LGE also has greater interaction with the right ventricle and the conduction system.

Inherited cardiomyopathies may have contributed to the increased risk of SCD events associated with sub-epicardial or multiple patterns of LGE and concomitant LGE in the septum and free-wall. For example, lamin cardiomyopathies are characterized by mid-wall and sub-epicardial LGE in multiple locations and are associated with malignant arrhythmias [@bib16], [@bib17]. It is recognized that LV forms of arrhythmogenic cardiomyopathy constitute part of the DCM spectrum [@bib16]. Although cases of suspected arrhythmogenic right ventricular cardiomyopathy were excluded, it is possible that our cohort included left-dominant disease, characterized by sub-epicardial fibrofatty replacement. This reflects "real-world" clinical populations. Genetic substrate and fatty infiltration are likely to predispose to arrhythmias in this group [@bib18].

We also show a nonlinear relationship between LGE extent and outcome, such that small degrees of fibrosis are associated with a large increase in risk, particularly with regards to SCD events. This may be explained by the multifactorial disease process. Replacement fibrosis is 1 of several processes contributing to ventricular arrhythmogenesis [@bib3]. It is likely that the synergistic presence of multiple features leads to ventricular arrhythmia rather than 1 factor in a linear dose-dependent manner. In addition, it appears that risk is influenced by fibrosis microstructure and heterogeneity, not simply mass. Areas of scar with the greatest heterogeneity will cause the largest variation in conduction velocities and the greatest chance of creating re-entrant arrhythmia. Computational scar modeling offers the potential to provide important insights [@bib19].

Localized LGE at the ventricular insertion areas is common, even in healthy volunteers. What this represents and its significance is uncertain. Examining this was beyond the scope of this study; therefore, localized LGE at the ventricular insertion areas was not included. Quantifying the "gray-zone" surrounding an area of replacement fibrosis was proposed in the context of myocardial infarction [@bib20]. There is a lack of histologic correlation examining this concept in DCM. Given the ambiguity over what this technique measures in DCM, we chose not to include it in our analysis.

Study limitations {#sec3.1}
-----------------

Single-center studies are susceptible to selection bias. However, our registry includes patients with a complete spectrum of disease severity referred from secondary and tertiary centers for a range of common indications. In addition, the baseline characteristics are similar to other studies [@bib2]. Although data from a proportion of patients have been presented in previous studies [@bib1], [@bib4], patients in this larger cohort had extended follow-up for this investigation. The large number of patients and events affords greater statistical power and enables the investigation of multiple statistical models. The smaller number of patients in sub-groups such as those with focal or sub-epicardial LGE does, however, limit the interpretation of this specific data.

We recognize that not all arrhythmias resulting in appropriate shocks may have resulted in SCD if untreated. However, we have selected the most robust definition available, excluding antitachycardia pacing [@bib8]. We acknowledge that the use of different contrast agents has the potential to impact LGE quantification. However, there was no difference in the quantity, pattern, or location of LGE for patients scanned with gadobutrol compared to gadopentetate dimeglumine. In addition, the associations between LGE and outcome remain similar when patients are divided based on contrast agent and there was no difference in the estimated effect of LGE on outcome between groups ([Supplemental Table 7](#appsec1){ref-type="sec"}). The impact of the use of different contrast agents on the results of the study, therefore, appears to be minimal.

Parametric mapping was not available at the outset of the current study and was therefore not included in the analysis. This technique has the advantage of identifying diffuse myocardial changes which LGE imaging may not detect. Previous work has shown associations between native T1 values and mortality and heart failure outcomes in DCM [@bib21]. Given the possible role of diffuse fibrosis in arrhythmia generation and heart failure, parametric mapping offers hope in the identification of those at risk of adverse outcomes. We eagerly await further data examining the incremental value of parametric mapping. Our data suggest the need to examine the incremental value of this technique in addition to the presence of septal LGE.

Conclusions {#sec4}
===========

We show a large increase in all-cause mortality and SCD risk with small amounts of LGE. The incremental value of LGE extent is therefore limited. In addition, we show that septal LGE is associated with all-cause mortality and concomitant LGE in the septum and free-wall is associated with the greatest risk of SCD events.Perspectives**COMPETENCY IN MEDICAL KNOWLEDGE:** The presence of even small degrees of LGE is associated with an increased risk of death and SCD events. The presence of septal LGE is the best marker of mortality risk whilst the presence of concomitant LGE in the septum and free-wall confers the highest risk of SCD events.**TRANSLATIONAL OUTLOOK:** Randomized trials are needed to investigate whether patients with LGE gain benefit from targeted therapies, such as ICD implantation or novel antifibrotic agents.

Appendix {#appsec1}
========

Supplemental Figures 1--7 and Supplemental Tables 1--7
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[^1]: ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; BSA = body surface area; CMR = cardiovascular magnetic resonance; DCM = dilated cardiomyopathy; LAVi = indexed left atrial volume; LBBB = left bundle branch block; LGE = late gadolinium enhancement; LV = left ventricular; LVEDVi = indexed left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; RVEDVi = indexed right ventricular end-diastolic volume; RVEF = right ventricular ejection fraction; SCD = sudden cardiac death.

[^2]: Values are mean ± SD or n (%).

[^3]: Kruskal-Wallis Rank Test for continuous variables; Fisher Exact Test for categorical variables.

[^4]: Values are n or n (%) unless otherwise indicated.

[^5]: p values are quoted for each model overall and for the individual components.

[^6]: AIC = Akaike information criterion; C statistic = Harrell's C-statistic; CI = confidence intervals; HR = hazard ratio; Pts = number of patients in each sub-group; other abbreviations as in [Table 1](#tbl1){ref-type="table"}.

[^7]: The model with the smallest Akaike information criterion and the most optimal for prediction of all-cause mortality.

[^8]: Values are n or n (%) unless otherwise indicated.

[^9]: p values are quoted for each model overall and for the individual components.

[^10]: ASCD = aborted sudden cardiac death; all other abbreviations as in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}.

[^11]: The model with the smallest AIC and the most optimal for prediction of SCD.
